A Study Investigating the Safety, Absorption, and Elimination of MB04, a New Compound That May Potentially be Used in the Treatment of Autoimmune Disorders

NCT06392074 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

141

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Volunteers

Interventions

DRUG: MB04
DRUG: US License Enbrel
DRUG: EU Source Enbrel

Sponsor

mAbxience Research S.L.